Mein Warenkorb

HLA-A*0201 & B2M & Vaccinia virus (IMYDIINSV)

HLA-A*0201 & B2M & Vaccinia virus (IMYDIINSV) Produktliste

  • Attribut

    Protein (1)

  • Produktbibliothek

    Online (1)

  • Spezies

    Human (1)

  • Etikett

    His Tag & Avi Tag (1)

  • Marker

    Biotin-labeled (1)

ProduktnummerSpeziesExpressionssystemProduktbeschreibungProteinstrukturReinheitEigenschaftenVorbestellen/Bestellen
Human
HEK293
Biotinylated Human HLA-A*02:01&B2M&Vaccinia virus (IMYDIINSV) Complex Protein (Monomer, MALS verified) In den Warenkorb legen
Gesamtmenge1
  • 1

HLA-A*0201 & B2M & Vaccinia virus (IMYDIINSV) Molekülhintergrund

Among the nonvirion proteins of the vaccinia virus (VACV), a 94-kDa long protein is most abundantly present; the protein is a truncated form of the 150-kDa A-type inclusion (ATI) protein of the cowpox virus encoded by the ati gene. This VACV protein does not form intracellular ATIs, being as it is a major immunogen upon infection/immunization of humans or animals with the VACV. variants demonstrated that the mutant LIVPΔati elicits a stronger protective response compared to the parent LIVP. The human HLA-A*0201 Vaccinia virus IMYDIINSV complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and IMYDIINSV peptide of the vaccinia virus.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Olaptesed PegolNOX-A12Phase 2 ClinicalNoxxon PharmaHematopoietic stem cell transplantation (HSCT); Glioblastoma; Pancreatic Neoplasms; Multiple Myeloma; Colorectal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell
Details
PTX-9908PTX-9908Phase 2 ClinicalPertinax TherapeuticsCarcinoma, Hepatocellular
Details
Emilimogene sigulactibacILP100hPhase 2 ClinicalIlya Pharma ABDiabetic Foot; Wounds and Injuries
Details
JVS-100JVS-100; SRX-100; ACRX-100; GP-51801; GP51801Phase 1 ClinicalCleveland ClinicHeart Failure; Ischemia; Surgical Wound; Peripheral Arterial Disease
Details
CK-0804CK-0804Phase 1 ClinicalCellenkos IncPrimary Myelofibrosis
Details
Dociparstat sodiumODSH; CX-01; PGX-100; PGX-ODSH-2013-AML-1Phase 1 ClinicalParingenixCoronavirus Disease 2019 (COVID-19); Pancreatic Neoplasms; Myelodysplastic Syndromes; Protein-Losing Enteropathies; Pulmonary Disease, Chronic Obstructive; Leukemia, Myeloid, Acute; Acute Lung Injury
Details
MyoCell SDF-1MyoCell SDF-1ClinicalU.S. Stem CellHeart Failure
Details
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns